Metastatic hormone-sensitive prostate cancer (mHSPC) is a common type of advanced prostate cancers that has metastasized. Therefore, the research on the diagnosis and treatment of mHSPC is of high value. Recent studies on the diagnosis and treatment of mHSPC mainly focus on the use of biological characteristics of mHSPC for targeted tracking diagnosis and androgen deprivation therapy (ADT), taxane-based chemohormonal therapy, new androgen receptor targeting agent, radiotherapy, immunotherapy, etc. A number of studies have shown that the improvement of molecular detection technology for mHSPC can provide great help for the diagnosis and prognosis of patients. Among many chemotherapeutic drugs of mHSPC, abiraterone plus prednisone have a better therapeutic effect. In addition, new androgen receptor targeting agent such as apalutamide have been proved to improve safety and improve the quality of patients’ life. Individualized treatment with corresponding combination therapy for different mHSPC patients will improve the prognosis effectively. In the future, mHSPC chemotherapy drugs with lower adverse reactions need to be developed.